Overview
David Page, PhD, serves as chair of the Department of Biostatistics and Bioinformatics and professor of biostatistics and bioinformatics and computer science at Duke University. He joined Duke in 2019. Dr. Page works on algorithms for data mining and machine learning and their applications to biomedical data. His research focuses on machine learning methods for complex multi-relational data, such as electronic health records, high throughput genetic and molecular data, and irregular temporal data, and methods that find causal relationships and produce human-interpretable output.
Dr. Page co-leads the Duke Discovery AI initiative which unites computational scientists, biologists, and engineers across the university to advance integration of artificial intelligence with biological research at the molecular, cellular, and organism scales. Together they train the next generation of scientists in biological systems and computational methods.
During his 20 years at the University of Wisconsin-Madison, Dr. Page taught courses titled Advanced AI, Machine Learning, Bioinformatics, and Health Informatics, in addition to special topics courses on Statistical Relational Learning and Learning Biological Networks. Dr. Page was a Kellett and Vilas Distinguished Achievement Professor and was Director of the Informatics Core of the Carbone Cancer Center. He served on scientific advisory and leadership committees for the Observational Medical Outcomes Partnership (OMOP), the International Warfarin Pharmacogenetics Consortium (IWPC), the Wisconsin Genomics Initiative, and UW-Madison's Institute for Clinical & Translational Science. Dr. Page received his PhD in computer science from the University of Illinois at Urbana-Champaign, where his dissertation focused on theoretical aspects of machine learning. He first became involved in biomedical applications of machine learning during his post-doc working with Dr. Stephen Muggleton at Oxford University.
Current Duke Appointments & Affiliations
Recent Scholarly Works
Stratifying Risk and Treatment Benefit: A Model Predicting Overall Survival in Men with Metastatic De Novo Hormone-sensitive Prostate Cancer in Trials Investigating Docetaxel (the STOPCAP Collaboration).
Journal article Eur Urol Focus · June 2026 BACKGROUND AND OBJECTIVE: This study aimed to develop and validate a prognostic model for overall survival (OS) in men with de novo metastatic hormone-sensitive prostate cancer (mHSPC), using clinical factors from phase 3 trials to improve survival predict ... Full text Link to item CitePathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer.
Journal article Eur Urol · April 2026 BACKGROUND AND OBJECTIVE: Although validated prognostic models exist for men with metastatic castration-resistant prostate cancer (mCRPC), current tools do not incorporate genomic biomarkers such as circulating tumor DNA (ctDNA) aneuploidy or pathogenic ge ... Full text Link to item CiteThe LURN Study-What Have We "LURN"ed So Far?
Journal article Neurourol Urodyn · April 2026 LURN was established by the NIDDK to study LUTS with a holistic approach, focusing on urinary urgency. LURN has developed patient-reported outcome instruments to better measure LUTS in men and women. LURN SI-29 can be used for clinical research. LURN SI-10 ... Full text Link to item CiteRecent Grants
Computational Biology and Bioinformatics Training Grant
Inst. Training Prgm or CMECo-Principal Investigator · Awarded by National Institutes of Health · 2026 - 2031Advancing a Holistic Understanding of Variability in Lived Experience with Sickle Cell Pain
ResearchCo-Principal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2025 - 2030Deprescribing Decision-Making using Machine Learning Individualized Treatment Rules to Improve CNS Polypharmacy
ResearchCo Investigator · Awarded by National Institute on Aging · 2024 - 2029View All Grants